5/16
08:15 am
alim
Alimera Sciences, Inc. (NASDAQ: ALIM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Low
Report
Alimera Sciences, Inc. (NASDAQ: ALIM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
5/14
07:42 am
alim
Alimera Sciences Reports First Quarter 2024 Results [Yahoo! Finance]
Medium
Report
Alimera Sciences Reports First Quarter 2024 Results [Yahoo! Finance]
5/14
07:30 am
alim
Alimera Sciences Reports First Quarter 2024 Results
Medium
Report
Alimera Sciences Reports First Quarter 2024 Results
5/7
08:14 am
alim
Alimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress Conferences [Yahoo! Finance]
Medium
Report
Alimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress Conferences [Yahoo! Finance]
5/7
08:00 am
alim
Alimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress Conferences
Medium
Report
Alimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress Conferences
4/30
08:17 am
alim
Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update [Yahoo! Finance]
Low
Report
Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update [Yahoo! Finance]
4/30
08:00 am
alim
Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update
Low
Report
Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update
4/30
02:07 am
alim
Alimera Sciences, Inc. (NASDAQ: ALIM) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Low
Report
Alimera Sciences, Inc. (NASDAQ: ALIM) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
4/22
11:06 pm
alim
Alimera Sciences, Inc. (NASDAQ: ALIM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
Alimera Sciences, Inc. (NASDAQ: ALIM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
4/12
11:05 pm
alim
Alimera Sciences, Inc. (NASDAQ: ALIM) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Low
Report
Alimera Sciences, Inc. (NASDAQ: ALIM) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
4/4
11:04 pm
alim
Alimera Sciences, Inc. (NASDAQ: ALIM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
Alimera Sciences, Inc. (NASDAQ: ALIM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
4/2
10:26 am
alim
Luckie & Company Acquires Marbury Creative Group [Yahoo! Finance]
Medium
Report
Luckie & Company Acquires Marbury Creative Group [Yahoo! Finance]
3/25
08:05 am
alim
Alimera Sciences, Inc. (NASDAQ: ALIM) is now covered by analysts at Maxim Group. They set a "buy" rating and a $10.00 price target on the stock.
Low
Report
Alimera Sciences, Inc. (NASDAQ: ALIM) is now covered by analysts at Maxim Group. They set a "buy" rating and a $10.00 price target on the stock.
3/20
08:11 am
alim
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Medium
Report
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
3/20
08:00 am
alim
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/19
08:13 am
alim
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network [Yahoo! Finance]
Low
Report
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network [Yahoo! Finance]
3/19
08:00 am
alim
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network
Low
Report
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network
3/13
09:36 am
alim
New Strong Sell Stocks for March 13th [Yahoo! Finance]
Low
Report
New Strong Sell Stocks for March 13th [Yahoo! Finance]
3/8
10:14 am
alim
Alimera Sciences, Inc. (NASDAQ:ALIM) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Alimera Sciences, Inc. (NASDAQ:ALIM) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/7
02:12 pm
alim
Alimera Sciences Inc (ALIM) Reports Significant Revenue Growth in Q4 and Full Year 2023 [Yahoo! Finance]
Low
Report
Alimera Sciences Inc (ALIM) Reports Significant Revenue Growth in Q4 and Full Year 2023 [Yahoo! Finance]
3/7
10:50 am
alim
Alimera Sciences (ALIM) Reports Q4 Loss, Tops Revenue Estimates [Yahoo! Finance]
Low
Report
Alimera Sciences (ALIM) Reports Q4 Loss, Tops Revenue Estimates [Yahoo! Finance]
3/7
07:36 am
alim
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results [Yahoo! Finance]
Low
Report
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results [Yahoo! Finance]
3/7
07:30 am
alim
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
Low
Report
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
3/6
06:14 am
alim
Alimera Sciences, Inc. (NASDAQ:ALIM) Has Found A Path To Profitability [Yahoo! Finance]
Low
Report
Alimera Sciences, Inc. (NASDAQ:ALIM) Has Found A Path To Profitability [Yahoo! Finance]
2/29
08:14 am
alim
Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update [Yahoo! Finance]
Medium
Report
Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update [Yahoo! Finance]